ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.
 PMID: 24831260       2015       Antiviral therapy
4Method: Sequences were assembled with Sequencher (version 4.9; Gene Codes Corp, Ann Arbor, Ml) and submitted to the Stanford University HIV Drug Resistance Database (version 6.3.0; http://hivdb.stanford.edu on August 21, 2013) to identify ""major"" INSTI mutations (T66I, E92Q, G140S, Y143C/H/R, S147G, Q148H/K/R, and N155H)."
Abstract: Consensus sequencing identified no subjects with major INSTI mutations (T66I, E92Q, G140S, Y143C/H/R, S147G,  PMID: 25367908       2015       Antimicrobial agents and chemotherapy
Abstract: GSK1265744 demonstrated activity against SDM clones containing the raltegravir (RAL)-resistant Y143R, Q148K, N155H, and G140S/Q148H signature variants (FC less than 6.1), while these mutants had a high FC in the EC50 for RAL (11 to >130).


  High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.
 PMID: 25386009       2015       The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Among the 92 patients analysed, 32 (35%) showed resistance to dolutegravir, in most cases associated with the combination of Q148H/R/K with G140S/A mutations.


  Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.
 PMID: 25691633       2015       Antimicrobial agents and chemotherapy
Abstract: E138K and G140S, as secondary substitutions to Q148H, Q148K, or Q148R, were associated with partial recovery in viral infectivity and/or INSTI resistance.
Abstract: In the Q148H, Q148K, or Q148R mutants, G140S/Q148H, E138K/Q148K, E138K/Q148R, and G140S/Q148R secondary mutations were identified with each INSTI and showed high resistance to RAL o


  In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.
 PMID: 25808007       2015       Retrovirology
Abstract: Integrase substitutions E92Q, Y143C, E92Q + Y143C, and Q148R conferred relatively low levels of resistance to dolutegravir in HIV-2ROD9 (2- to 6-fold), but Q148K, E92Q + N155H, T97A + N155H and
Abstract: In contrast, HIV-1NL4-3 mutants E92Q + N155H, G140S + Q148R, and T97A + Y143C showed 2-fold, 4-fold, and no increase in EC50, respectively, relative to the parental strain.


  [Resistance profile and genetic barrier of dolutegravir].
 PMID: 25858608       2015       Enfermedades infecciosas y microbiologia clinica
Abstract: Dolutegravir displays in vitro activity against mutant HIV-1 harboring any isolated resistance mutations selected during failures to raltegravir or elvitegravir (Y143C/H/, N155H, Q148H/K/R, E92G/Q, T66A/I/K, T97A, E138A/K, G140A/S).


  Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.
 PMID: 25927004       2015       Acta naturae
Abstract: Its negative effect was partially compensated by the secondary mutations E138K and G140S.
Abstract: To assess the impact of drug resistance mutations on the activity of IN of HIV-1 subtype A strain FSU-A, which is dominant in Russia, variants of the consensus IN of this subtype containing the primary resistance mutations G118R and Q148K and secondary compensatory substitutions E138K and G140S were prepared and characterized.
Conclusion: Recombinant IN activity reduced by drug resistant mutations usually corresponds to a reduced replicative capacity of the mutant virus; therefore, we can expect the emergence and fixation of drug-resistant variants of HIV-1 FSU


  Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
 PMID: 25956162       2015       Antiviral research
Abstract: Notably, the S119R polymorphism contributed to a significant (5.9-fold) increase in dolutegravir resistance caused by G140S/Q148H.


  Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.
 PMID: 26198244       2015       Viruses
Table: G140S


  Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
 PMID: 26205139       2015       The Journal of antimicrobial chemotherapy
Abstract: CONCLUSIONS: Combination of N155H, G140S and Q148H mutations originating from two distinct resistance pathways to raltegravir or elvitegravir led to a high level of dolutegravir resistance.
Abstract: RESULTS: Our data showed that the combination of N155H, G140S and Q148H mutations led to strong resistance to dolutegravir.



Browser Board

 Co-occurred Entities




   Filtrator